European Cancer Collaboration Unit
The European Cancer Collaboration Unit at the Oslo University Hospital, Radiumhospitalet is working to strengthen Oslo University Hospital and Norway’s roles in European cooperation in cancer treatment and research through participation in several EU-funded projects.
EU- projects
The unit coordinates Oslo University Hospital’s participation in several cancer-related European projects, including
EUnetCCC – The European Network of Comprehensive Cancer Centres
EUnetCCC’s ambition is to improve cancer care in Europe and ensure that all Europeans have equitable access to state-of-the-art medical care and the most advanced therapeutic innovations. The project runs over a period of four years, from October 2024 until the end of September 2028, and brings together 163 partner institutions from 31 countries across Europe.
Their aim is that by the time the project is completed, at least 90 percent of eligible patients across Europe should have access to high-quality, evidence-based care throughout the entire cancer continuum, regardless of their geographical location. To this end, EUnetCCC has developed its own certification scheme for hospitals in Europe that want to become certified as Comprehensive Cancer Centres (CCCs) and aim to certify at least 100 CCCs by 2028.
The project will also create a cohesive, integrated network of centres that are either certified as CCCs or are in the process of preparing for certification, with the aim to increase knowledge sharing across hospitals in Europe. Oslo University Hospital has a leading role in the project, which has been granted almost 90 million euros in financial support from the EU4Health programme.
CCI4EU – Comprehensive Cancer Infrastructures for Europe
CC14EU aims to improve cancer care, cancer research and cancer education in Europe through developing recommendations for how to structure future capacity building projects, and for how to develop and scale up national and regional comprehensive cancer infrastructures.
The project brings together 54 partner institutions from 32 European countries, has received almost 10 million euros in financial support from the EU’s Horizon Europe research and innovation programme, and runs over a period of three years, from May 2023 until the end of April 2026. .
JANE2 – Joint Action Networks of Expertise on Cancer
Jane2 aims establish seven new Networks of Expertise that are focusing on different topics within cancer care. Together, these should contribute to improving cancer care in Europe, for example by producing clinical practice guidelines and developing quality criteria.
The project runs over a period of four years, from November 2024 until the end of October 2028. It brings together 121 partner institutions from 29 European countries and has been granted more than 40 million euros in financial support from the EU under the EU’s Beating Cancer Plan and the programme EU4Health.
eCAN Plus – Enhancing the Digital Capabilities of Cancer Centres in Europe to Improve Prevention and Care
The eCANplus Joint Action has been granted almost 20 million euros in financial support from the EU4Health programme, and runs over a period of four years, from May 2025 until the end of April 2029. The project encompasses 83 partner institutions from 23 European Countries, and together these are working to enhance digital capabilities and the use of electronic health data at cancer centres in Europe.
Both patients and health care personnel are expected to benefit from increased digitisation, and it should also lead to better cancer care and increased collaboration between different cancer centres in Europe. The project also aims to develop and implement a solid, integrated framework for the remote follow-up and telemonitoring of cancer patients throughout Europe
JA PCM – Joint Action on Personalised Cancer Medicine
Personalised cancer medicine using personal medical history, physiological status and genomic profiling in combination with technologies like imaging are key in cancer management, from prevention to end-of-life care, but there are currently significant disparities across European countries regarding patients’ access personalised cancer care. The Joint Action on Personalised Cancer Medicine (JA PCM) thus aims to build a cross-border network for personalised cancer medicine by uniting European countries and key stakeholders, supporting its long-term uptake across Europe.
The project brings together more than 140 partner institutions from 29 European countries, runs over a period of four years, from November 2025 until the end of October 2029, and has been granted more than 25 million euros in support from the EU4Health programme.